Pharmaceutical manufacturers are focused on increasing access to affordable medications to provide novel options for patients and pharmacists, thereby addressing the limited availability of erythromycin tablets, which in turn is expected to augment market growth. For instance, in March, 2018, Amneal Pharmaceuticals received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The erythromycin product is a therapeutic equivalent for the reference listed drug (RLD) erythromycin tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1780

Moreover, in September 2016, ANI Pharmaceuticals, Inc. launched Erythromycin Ethylsuccinate for oral suspension 200mg/5mL indicated as a treatment for various infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires disease, pertussis, and others.

Moreover, rising prevalence of various infectious diseases including respiratory tract infections is a major factor expected to augment growth of the erythromycin market size in the near future. According to the study by Bill & Melinda Gates Foundation, 2015, an estimated 2.74 million deaths were recorded due to lower respiratory tract infections (LRIs) and 103.0 million disability-adjusted life-years (DALYs) globally. This is expected to increase adoption of antibiotics.

Regional segmentation of the global erythromycin market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America erythromycin market is expected to hold a dominant position over the forecast period, owing to rising number of regulatory approvals of drugs by regulatory agencies to address the unmet medical needs of the patients and increasing prevalence of skin and soft tissue infections.

For instance, in November, 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Erythromycin and Benzoyl Peroxide Topical Gel USP, 3-5% an FDA-approved generic version of Valeant International’s Benzamycin Gel, 3-5%. According to the Division of Infectious Diseases, Los Angeles BioMedical Research Center, 2015, skin and soft tissue infections (SSTIs) are a common reason to seek medical care in the U.S. as they can lead to complications with significant morbidity, including hospitalization, surgical procedures, or death.

For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/ongoing-insight/erythromycin-market-1780

Manufactures are focused on development, manufacturing, and marketing of multisource and branded pharmaceuticals, thereby augmenting the market growth. For instance, in July 2017, Teligent, Inc., a generic pharmaceutical company, received approval for its abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Erythromycin Topical Gel USP, 2%. Furthermore, in 2010, Akorn, Inc. received the U.S. Food and Drug Administration (FDA) approval for the company’s Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g.

Key players operating in the global erythromycin market include Ani Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis Pharmaceuticals, Teligent, Inc., Abbvie, Inc., Abbott Laboratories, Pfizer, Inc., Sanofi-Aventis, and Allergan, Plc.